Trial Profile

A Phase1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMG-007 (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Proof of concept
Sponsors Inmagene

Most Recent Events

12 Nov 2025 According to an Inmagene media release, data from this trial will be presented at the upcoming 6th Annual Inflammatory Skin Disease Summit (ISDS) in New York November 12-15, 2025.
09 Jan 2025 Positive topline results from phase 2a were presented in an Inmagene media release.
15 May 2024 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com